Your browser doesn't support javascript.
loading
Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial.
Goetz, M P; Bagegni, N A; Batist, G; Brufsky, A; Cristofanilli, M A; Damodaran, S; Daniel, B R; Fleming, G F; Gradishar, W J; Graff, S L; Grosse Perdekamp, M T; Hamilton, E; Lavasani, S; Moreno-Aspitia, A; O'Connor, T; Pluard, T J; Rugo, H S; Sammons, S L; Schwartzberg, L S; Stover, D G; Vidal, G A; Wang, G; Warner, E; Yerushalmi, R; Plourde, P V; Portman, D J; Gal-Yam, E N.
Afiliación
  • Goetz MP; Department of Oncology, Mayo Clinic, Rochester. Electronic address: goetz.matthew@mayo.edu.
  • Bagegni NA; Division of Oncology, Washington University School of Medicine, St. Louis, USA.
  • Batist G; Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
  • Brufsky A; University of Pittsburgh Medical Center-Magee Women's Hospital, Pittsburgh.
  • Cristofanilli MA; Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York.
  • Damodaran S; The University of Texas MD Anderson Cancer Center, Department of Breast Medical Oncology, Houston.
  • Daniel BR; Tennessee Oncology, Chattanooga.
  • Fleming GF; The University of Chicago Medical Center, Chicago.
  • Gradishar WJ; Division of Hematology/Oncology, Northwestern University, Chicago.
  • Graff SL; Lifespan Cancer Institute/Legorreta Cancer Center at Brown University, Providence.
  • Grosse Perdekamp MT; Carle Cancer Center, Carle Foundation Hospital, Urbana.
  • Hamilton E; Sarah Cannon Research Institute/Tennessee Oncology, Nashville.
  • Lavasani S; Division of Hematology and Medical Oncology, UC Irvine, Orange.
  • Moreno-Aspitia A; Division of Hematology/Oncology, Mayo Clinic, Jacksonville.
  • O'Connor T; Roswell Park Comprehensive Cancer Center, Department of Medicine, Buffalo.
  • Pluard TJ; Saint Luke's Cancer Institute, Kansas City.
  • Rugo HS; Department of Medicine (Hematology/Oncology), University of California San Francisco, San Francisco.
  • Sammons SL; Dana Farber Cancer Institute, Harvard Medical School, Boston.
  • Schwartzberg LS; Pennington Cancer Institute, University of Nevada, Reno.
  • Stover DG; Ohio State University Comprehensive Cancer Center, Ohio State University, Columbus.
  • Vidal GA; Breast Oncology Division, West Cancer Center, Memphis.
  • Wang G; Medical Oncology, Miami Cancer Institute at Baptist Health, Miami, USA.
  • Warner E; Division of Medical Oncology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
  • Yerushalmi R; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Tel-Aviv University, Tel-Aviv, Israel.
  • Plourde PV; Sermonix Pharmaceuticals, Columbus, USA.
  • Portman DJ; Sermonix Pharmaceuticals, Columbus, USA.
  • Gal-Yam EN; Breast Oncology Institute, Sheba Medical Center, Ramat Gan, Israel.
Ann Oncol ; 34(12): 1141-1151, 2023 12.
Article en En | MEDLINE | ID: mdl-38072514
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama Límite: Female / Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama Límite: Female / Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article